Patents Assigned to GlaxoSmithKline Biologicals, s.a.
  • Publication number: 20210277038
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: September 5, 2016
    Publication date: September 9, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Publication number: 20210269486
    Abstract: The invention provides adenoviral vectors comprising transgenes encoding Lyssaviral antigens. The vectors can be used to produce vaccines for the prophylaxis, amelioration and treatment of diseases caused by Lyssaviral diseases, e.g., rabies.
    Type: Application
    Filed: December 8, 2017
    Publication date: September 2, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Virginia AMMENDOLA, Stefaano COLLOCA, Alessandra VITELLI, Benjamin Wizel
  • Patent number: 11040095
    Abstract: HRV VP2 proteins useful as components of immunogenic compositions for the induction of cross-reactive cell-mediated immunity against human rhinovirus infection; nucleic acid constructs encoding such HRV VP2 proteins.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: June 22, 2021
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Catherine Marie Ghislaine Gerard, Sandra Giannini, Julien Thierry Massaux
  • Publication number: 20210162042
    Abstract: The present invention relates to compositions and methods for manufacturing an adjuvant comprising a saponin using a microfluidic device and to aspects thereof.
    Type: Application
    Filed: March 23, 2018
    Publication date: June 3, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Pol HARVENGT, Philippe JEHOULET, Loic LE GOURRIEREC, Demostene SIFAKAKIS, Laurent STRODIOT
  • Publication number: 20210128474
    Abstract: Methods for manufacturing a non-viral delivery system comprising a liposome encapsulating an RNA using a microfluidic device and compositions for use therein are provided.
    Type: Application
    Filed: May 30, 2018
    Publication date: May 6, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Laurent Bernard Jean STRODIOT, Geraldine MINET
  • Patent number: 10967057
    Abstract: Compounds useful as components of immunogenic compositions for the induction of an immunogenic response in a subject against viral infection, methods for their use in treatment, and processes for their manufacture are provided herein. The compounds comprise a nucleic acid construct comprising a sequence which encodes a Zika virus antigen. A particular embodiment is a nucleic acid-based vaccine construct encoding a polypeptide comprising a full-length Zika virus prME antigen. A particular embodiment is a self-replicating RNA molecule comprising a construct encoding a polypeptide comprising a full-length Zika virus prME antigen.
    Type: Grant
    Filed: June 1, 2017
    Date of Patent: April 6, 2021
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Dong Yu, Mayuri Sharma
  • Publication number: 20210085772
    Abstract: The present invention is directed to a bioconjugate vaccine, such as an O 1-bioconjugate vaccine, comprising: a protein carrier comprising a protein carrier containing at least one consensus sequence, DIE-X-N-Z-S/T, wherein X and Z may be any natural amino acid except proline; at least one antigenic polysaccharide from at least one pathogenic bacterium, linked to the protein carrier; and, optionally, an adjuvant. In another aspect, the present invention is directed to a method of producing an O 1-bioconjugate in a bioreactor comprising a number steps.
    Type: Application
    Filed: October 2, 2020
    Publication date: March 25, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Fabiana FERNANDEZ, Michael KOWARIK, Michael WACKER, Michael WETTER
  • Publication number: 20200323896
    Abstract: RNA encoding an immunogen is co-delivered to non-immune cells at the site of delivery and also to immune cells which infiltrate the site of delivery. The responses of these two cell types to the same delivered RNA lead to two different effects, which interact to produce a strong immune response against the immunogen. The non-immune cells translate the RNA and express the immunogen. Infiltrating immune cells respond to the RNA by expressing type I interferons and pro-inflammatory cytokines which produce a local adjuvant effect which acts on the immunogen-expressing non-immune cells to upregulate major histocompatibility complex expression, thereby increasing presentation of the translated protein to T cells. The effects on the immune and non-immune cells can be achieved by a single delivery of a single RNA e.g. by a single injection.
    Type: Application
    Filed: January 13, 2020
    Publication date: October 15, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrew GEALL, Katrin RAMSAUER, Gillis OTTEN, Christian Walter MANDL
  • Patent number: 10695424
    Abstract: The present invention provides compositions, methods and processes for the maturation of submicron liposome compositions comprising a lipid, a sterol, and a saponin.
    Type: Grant
    Filed: December 5, 2017
    Date of Patent: June 30, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe Cara, Veronique Monique Roberte Henderickx, Vinciane Martha De Cupere, Carine Berthe Ghislaine De Kesel
  • Patent number: 10688168
    Abstract: Methods and uses are provided for inducing an immune response comprising at least two administrations of an immunogenic composition comprising an M72 related antigen and wherein a subsequent administration is delayed.
    Type: Grant
    Filed: April 2, 2015
    Date of Patent: June 23, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: William Ripley Ballou, Jr., Marie-Ange Demoitie, Marie-Noelle Renelle Donner, Nadia Ouaked, Stephane Theophile Temmerman
  • Patent number: 10669318
    Abstract: The present invention relates to a process for conjugation of an antigen.
    Type: Grant
    Filed: March 5, 2012
    Date of Patent: June 2, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Pierre Duvivier, Ollivier Francis Nicolas Gavard
  • Patent number: 10646566
    Abstract: The present invention relates to immunogenic compositions and methods for producing them, and in particular, immunogenic compositions comprising a protein antigen cross linked to an oxoadenine adjuvant.
    Type: Grant
    Filed: March 9, 2016
    Date of Patent: May 12, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: David Burkhart, Michael Cochran, Christopher W Cluff, Daniel Larocque, Helene G Bazin-Lee, Julien St Jean
  • Patent number: 10646564
    Abstract: The present invention discloses an immunogenic composition comprising S. pneumoniae capsular saccharide conjugates from serotypes 19A and 19F wherein 19A is conjugated to a first bacterial toxoid and 19F is conjugated to a second bacterial toxoid. Vaccines, methods of making vaccines and uses of the vaccines are also described.
    Type: Grant
    Filed: February 21, 2019
    Date of Patent: May 12, 2020
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Ralph Leon Biemans, Nathalie Marie-Josephe Garcon, Philippe Vincent Hermand, Jan Poolman, Marcelle Paulette Van Mechelen
  • Patent number: 10639361
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: May 5, 2020
    Assignee: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventor: Martine Marchand
  • Publication number: 20200123571
    Abstract: The present invention relates to nucleic acid constructs capable of encoding antigenic peptides or polypeptides derived from multiple Human Papilloma Virus (HPV) early proteins, and to immunogenic compositions comprising such nucleic acid constructs and a pharmaceutically acceptable carrier. Such nucleic acid constructs and immunogenic compositions are useful in the treatment of persistent HPV infection and low-grade HPV lesions, particularly infections and lesions of human anogenital epithelial tissue, such as cervical epithelia.
    Type: Application
    Filed: September 27, 2017
    Publication date: April 23, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Wivine BURNY, Cindy CASTADO, Sandra GIANNINI, Julien Thierry MASSAUX
  • Publication number: 20200113830
    Abstract: Nucleic acid immunisation is achieved by delivering RNA encapsulated within a PEGylated liposome. The RNA encodes an immunogen of interest. The PEG has an average molecular mass above 3 kDa but less than 11 kDa. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer comprises at least one lipid which includes a polyethylene glycol moiety, such that polyethylene glycol is present on the liposome's exterior, wherein the average molecular mass of the polyethylene glycol is above 3 kDa but less than 11 kDa; and (ii) the aqueous core includes a RNA which encodes an immunogen.
    Type: Application
    Filed: December 16, 2019
    Publication date: April 16, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Andrew GEALL, Ayush VERMA
  • Publication number: 20200102405
    Abstract: A method of lipopolysaccharide (LPS) extraction from gram negative bacterial cells is provided, said method comprising a step of extracting LPS from the gram negative bacterial cell in a LPS extraction solution comprising a salt, water, an alcohol, and a further organic solvent. Compositions and uses of the extracted LPS are also provided.
    Type: Application
    Filed: December 21, 2016
    Publication date: April 2, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Jeffrey A. KERN, Chad FARRENBURG
  • Patent number: 10583185
    Abstract: Compositions and methods are described for inducing an immune response against extra-intestinal pathogenic Escherichia coli (ExPEC) to thereby provide immune protection against diseases associated with ExPEC. In particular, compositions and methods are described for using conjugates of E. coli polysaccharide antigens O25B, O1A, O2, and O6A covalently bound to a detoxified exotoxin A of Pseudomonas aeruginosa (EPA) carrier protein as vaccines for the prevention of invasive ExPEC disease caused by ExPEC serotypes O1A, O2, O6A and O25B.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: March 10, 2020
    Assignees: GlaxoSmithKline Biological S.A., Janssen Pharmaceuticals, Inc.
    Inventors: Jan Theunis Poolman, Bert Jacquemyn, Darren Robert Abbanat, Patricia Ibarra Yon, Peter Wilhelmus Maria Hermans, Michael Thomas Kowarik, Michael Lukas Wetter, Stefan Jochen Kemmler, Micha Andres Häuptle, Veronica Gambillara Fonck, Manuela Mally
  • Publication number: 20200061186
    Abstract: The present invention provides compositions, methods and processes for the maturation of submicron liposome compositions comprising a lipid, a sterol, and a saponin.
    Type: Application
    Filed: December 5, 2017
    Publication date: February 27, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: Philippe CARA, Veronique Monique Roberte HENDERICKX, Vinciane Martha DE CUPERE, Carine Berthe Ghislaine DE KESEL
  • Publication number: 20200023051
    Abstract: The present invention relates to the field of native outer membrane vesicles (nOMVs), particularly nOMVs having increased levels of lipoproteins on their surface and use of same in immunogenic compositions.
    Type: Application
    Filed: June 29, 2017
    Publication date: January 23, 2020
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Beatrice RICCHETTI, Isabel DELANY